Background Short-term interleukin-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears to be well tolerated. Objectives Safety and tolerability were assessed for up to 64 weeks of tildrakizumab therapy using pooled data from three randomized controlled trials for moderateto-severe psoriasis. Methods Data pools for the placebo-controlled (up to 16 weeks) and full trial periods (up to 64 weeks) were analysed (n = 2081). Results In the placebo-controlled period, frequencies of treatment-emergent adverse events (TEAEs; range 47Á9-54Á0%), serious TEAEs (range 1Á4-2Á3%), discontinuations due to AEs (range 0Á6-1Á9%), major adverse cardiovascular events (MACEs; range 0Á0-0Á1%) and severe infections (range 0Á0-0Á3%) were comparable between tildrakizumab 100 mg, tildrakizumab 200 mg, placebo and etanercept. In the full trial period, exposure-adjusted rates (patients per 100 patient-years) for TEAEs, serious TEAEs and discontinuations due to AEs with tildrakizumab 100 mg and 200 mg were lower than or comparable with the placebo rates, and lower than with etanercept. Exposure-adjusted rates of MACEs (range 0Á0-0Á5) and severe infections (range 0Á9-2Á0) were comparable among groups. No TEAEs of inflammatory bowel disease or suicide were reported. Candida skin infections were infrequent at frequencies of 0Á1%, 0Á3%, 0Á0% and 0Á0% for the tildrakizumab 100 mg, tildrakizumab 200 mg, placebo and etanercept groups, respectively, in the placebo-controlled period, and exposure-adjusted rates of 0Á2, 0Á7, 0Á0 and 0Á0, respectively, in the full trial period. Oral candidiasis was also infrequent. Conclusions Up to 64 weeks of tildrakizumab was well tolerated, with low rates of serious TEAEs, discontinuations due to AEs, and AEs of clinical interest.
What does this study add?
• Pooled analysis of three randomized controlled trials consolidates the safety and tolerability in a larger group of patients for up to 64 weeks of tildrakizumab treatment.
Targeting of cytokines involved in psoriasis pathogenesis has been a focus of therapy. Initially, tumour necrosis factor-a blockers became a successful treatment option, although these medications can be associated with infections and other sideeffects. [1] [2] [3] The importance of the interleukin (IL)-23-T helper (Th)17 pathway in psoriasis has fuelled the development of IL-23 inhibitors. [4] [5] [6] [7] [8] [9] IL-23 is elevated in psoriasis lesions, 10 and downregulation of IL-23 mRNA expression in lesions is associated with successful clinical responses to treatment. 11, 12 Furthermore, IL-23 drives activation of human Th17 cells, which subsequently promote chronic inflammation and produce cytokines with downstream effects characteristic of psoriasis, such as keratinocyte activation and hyperproliferation. 13, 14 Tildrakizumab is a high-affinity, humanized, IgG1j monoclonal antibody directed against the p19 subunit of IL-23. One phase II and two large phase III randomized controlled trials (RCTs) of tildrakizumab have been conducted in patients with moderate-to-severe chronic plaque psoriasis. 6, 9 Tildrakizumab appeared to be well tolerated in all three trials, with low frequencies of serious adverse events (AEs) and discontinuations due to AEs. Dose-associated risk of Candida albicans infections and inflammatory bowel disease has been reported with IL-17 blockers, [15] [16] [17] but not with the IL-23 inhibitors guselkumab or tildrakizumab. 4, 6 This suggests that IL-23-independent IL-17A production may be preserved during anti-IL-23 therapy and thus protect against development of these specific side-effects. The present analysis further assessed the safety and tolerability of tildrakizumab for up to 64 weeks of use in a large group of patients using pooled data from the three previously reported RCTs. 6, 9 In addition to candidiasis and inflammatory bowel disease, other important safety outcomes such as major adverse cardiovascular events (MACEs) and malignancy, which are possibly increased in patients with psoriasis vs. the general population, were assessed.
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Patients and methods
Trial designs
Pooled data from three multicentre, international RCTs -P05495 (phase II, NCT01225731), reSURFACE 1 (phase III, NCT01722331) and reSURFACE 2 (phase III, NCT01729754) -were included in this analysis. The trial details and primary results have been previously described. 6, 9 Patients in all three trials had moderate-to-severe plaque psoriasis defined as ≥ 10% body surface area involvement, Physician's Global Assessment ≥ 3 and Psoriasis Area and Severity Index (PASI) ≥ 12. Exclusion criteria related to safety outcomes are listed in Appendix S1 (see Supporting Information). In the P05495 trial, patients in part 1 (weeks 1-16) received subcutaneous tildrakizumab 5 mg, 25 mg, 100 mg or 200 mg, or placebo at weeks 0 and 4 ( Fig. S1a ; see Supporting Information). In part 2 (weeks 16-52), patients were rerandomized to various tildrakizumab doses based on responder status. In the reSURFACE 1 and 2 trials, patients in part 1 (weeks 1-12) received subcutaneous tildrakizumab 100 mg or 200 mg, or placebo at weeks 0 and 4 ( Fig. S1b, c ; see Supporting Information). In reSURFACE 2, etanercept (ETN) 50 mg administered twice weekly during part 1 was an additional treatment arm. Patients receiving placebo in part 1 of reSURFACE 1 and 2 were rerandomized to tildrakizumab 100 mg or 200 mg and received tildrakizumab at weeks 12, 16 and 28 and every subsequent 12 weeks. Patients receiving tildrakizumab in part 1 continued their originally randomized treatment and received a dose of study medication at week 16, and the patients in reSURFACE 2 who received ETN in part 1 continued their ETN treatment, but administered once weekly. Patients in part 3 (weeks 28-64 in reSURFACE 1 and weeks 28-52 in reSURFACE 2) were rerandomized to tildrakizumab 100 mg or 200 mg (or placebo in reSURFACE 1) based on responder (PASI ≥ 75; ≥ 75% improvement from baseline) and partial responder (PASI 50 to < 75) status and received treatment every 12 weeks. Responders in the ETN arm in reSURFACE 2 were discontinued at week 28; partial (PASI 50 to < 75) and nonresponders (PASI < 50) were assigned to tildrakizumab 200 mg. Each trial had a 20-week follow-up period after treatment completion or discontinuation.
Safety assessments
A serious AE was any AE that resulted in death, was life threatening, required hospitalization or prolongation of existing inpatient hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, was a cancer, was associated with an overdose or was considered another important medical event. 22 Confirmed
MACEs included nonfatal myocardial infarction, nonfatal stroke, and cardiovascular deaths that were confirmed as 'cardiovascular' or 'sudden'. All deaths and serious cardiovascular events were adjudicated by an external clinical adjudication committee. Severe infections were those that met the regulatory definition of a serious AE or required intravenous antibiotics. Prespecified events of clinical interest for the pooled analyses included severe infections, malignancies, nonmelanoma skin cancer, melanoma skin cancer, MACEs, injection-site reactions and drug-related hypersensitivity reactions.
Data analysis
Data pools of treatment-emergent AEs (TEAEs) for the placebo-controlled period and full trial period (52 weeks for P05495 and reSURFACE 2; 64 weeks for reSURFACE 1) were analysed. In the full trial period pool, patients who received multiple treatments were counted in each treatment received after adjustment for exposure. For patients who dropped out during the trial and entered the follow-up period, AEs occurring during the follow-up were included and were attributed to the last treatment received. Frequencies (patients with events divided by number of patients exposed) were calculated for safety outcomes in the placebo-controlled period. Exposure-adjusted rates (patients with events per 100 patient-years) were also calculated for specific AEs in the placebo-controlled period and for safety outcomes in the full trial period. Differences and 95% confidence intervals in frequencies between tildrakizumab treatments and placebo for the prespecified events of clinical interest in the placebo-controlled period were calculated based on the Miettinen and Nurminen method 23 with no information on strata included.
Results

Patients and exposure
In total, 2081 patients were treated with tildrakizumab 100 mg (n = 705), tildrakizumab 200 mg (n = 708), placebo (n = 355) or ETN (n = 313) and were included in the pooled analysis. Of the 2081 treated patients, 2000 (96Á1%)
completed part 1 and entered into part 2 of the studies. The baseline demographics and disease characteristics of the randomized patients were similar among the treatment groups ( Table 1) . The mean (range) durations of exposure during the full trial period were 48 (4-76) weeks for tildrakizumab 100 mg, 47 (4-76) weeks for tildrakizumab 200 mg and 19 (4-40) weeks for placebo. The mean (range) durations of exposure with ETN were 11Á4 (0Á5-12Á0) weeks for patients who received treatment twice weekly during part 1 and 15Á4 (0Á5-17Á0) weeks for patients who received treatment once weekly during part 2. The total exposure was 998 patientyears for tildrakizumab 100 mg, 929 patient-years for tildrakizumab 200 mg, 219 patient-years for placebo and 153 patient-years for ETN.
Overall safety
In the placebo-controlled period, the frequencies (patients divided by number of patients exposed) of TEAEs for tildrakizumab 100 mg, tildrakizumab 200 mg, placebo and ETN were 48Á2%, 47Á9%, 53Á8%, and 54Á0%, respectively ( Table 2 ). The most common TEAE in all treatment groups was nasopharyngitis (Fig. 1) . AEs related to the injection site were numerically higher in the ETN group than in the tildrakizumab groups or placebo group (Fig. 1) . Exposure-adjusted rates during the placebo-controlled period were consistent with the frequency data, confirming the higher rates for injection-site reactions with ETN compared with tildrakizumab treatment or placebo (Table S1 ; see Supporting Information).
In the full trial period, exposure-adjusted rates (patients per 100 patient-years) for TEAEs for tildrakizumab 100 mg, tildrakizumab 200 mg, placebo and ETN were 77Á0, 79Á3, 153Á5 and 148Á6, respectively ( Table 2 ). The highest exposure-adjusted rates for treatment-related AEs, serious TEAEs and discontinuations due to AEs were observed in the ETN group, whereas the rates with tildrakizumab treatment were lower than or comparable with placebo (Table 2) . Similarly to the placebo-controlled period, in the full trial period the most common TEAE in all treatment groups was nasopharyngitis, and AEs related to the injection site were highest in the ETN group. Seven deaths, all unrelated to treatment per investigator and study sponsor assessment, occurred during or after the trials. All deaths and serious cardiovascular events were adjudicated by an external clinical adjudication committee. Additional details of these cases can be found in Table S2 (see Supporting  Information) .
Prespecified adverse events of clinical interest
Frequencies of confirmed MACEs, malignancies, nonmelanoma skin cancer, drug-related hypersensitivity events and severe infections in the placebo-controlled period were low, ranging from 0Á0% to 0Á3% among the groups (Table S3 ; see Supporting Information). There were no events of melanoma skin cancer in any treatment group in the placebo-controlled period. The frequency of injection-site reactions was higher in the ETN group (17Á9%) than with tildrakizumab 100 mg (3Á4%), tildrakizumab 200 mg (4Á0%) or placebo (2Á3%). The two drug-related hypersensitivity reactions in patients on tildrakizumab treatment were assessed as being due to concomitant medications. There were no statistically significant differences between tildrakizumab treatment and placebo in the frequencies of any of the prespecified AEs (Table S3) .
Exposure-adjusted rates of confirmed MACEs in the full trial period ranged from 0Á0 to 0Á5. Exposure-adjusted rates of malignancies, nonmelanoma skin cancer and severe infections were low, ranging from 0Á9 to 2Á6 among the groups (Table S3) . Two patients (both on tildrakizumab 100 mg) developed melanoma skin cancer in the full trial period. Both cases were determined to be melanoma in situ. With the exception of malignant neoplastic processes involving the skin, the only malignancy reported more than once in patients receiving tildrakizumab was pancreatic cancer (two cases, both with tildrakizumab 200 mg). The exposure-adjusted rate of injection-site reactions was higher in the ETN group (40Á4) than with tildrakizumab 100 mg (3Á5), tildrakizumab 200 mg (4Á6) or placebo (5Á0).
Infections
In the placebo-controlled period, frequencies of infections were comparable for tildrakizumab 100 mg and 200 mg (22Á7% and 21Á9%, respectively) and placebo (22Á5%); all were comparable with ETN (23Á6%). In the full trial period, exposure-adjusted rates for infections with tildrakizumab 100 mg and 200 mg (48Á9 and 52Á6, respectively) were lower than with placebo and ETN (79Á5 and 86Á0, respectively). In all, 33 severe infections were identified (Table 3) .
One patient, a 58-year-old Asian man (birthplace unknown), had bone tuberculosis, which led to treatment discontinuation (tildrakizumab 200 mg). The patient reported occasional travel to Asia for business, but no other risk factors were noted. The original single-step Mantoux test in this patient was negative. After treatment, the tuberculosis resolved with no further sequelae. One sepsis event (tildrakizumab 200 mg) occurred 7 months after ending tildrakizumab treatment. Candida skin infections were infrequent in all treatment groups in the placebo-controlled period, at frequencies of 0Á1%, 0Á3%, 0Á0% and 0Á0% for the tildrakizumab 100 mg, tildrakizumab 200 mg, placebo and ETN groups, respectively. Exposure-adjusted rates for Candida skin infections in the full trial period were 0Á2, 0Á7, 0Á0 and 0Á0, respectively. Oral candidiasis was also infrequent, occurring at frequencies of 0Á1%, 0Á3%, 0Á0% and 0Á0% for the tildrakizumab 100 mg, tildrakizumab 200 mg, placebo and ETN groups, respectively, during the placebo-controlled period, and exposure-adjusted rates of 0Á2, 0Á7, 0Á0 and 0Á0, respectively, during the full trial period.
Other adverse events of interest
No TEAEs of new onset or exacerbation of pre-existing inflammatory bowel disease or multiple sclerosis were reported during the trials. No suicides were reported. One suicide attempt was reported in a patient who was receiving tildrakizumab 200 mg and who was on antipsychotic therapy for a known history of schizophrenia. The event was considered by the investigator to be unrelated to treatment.
Discussion
This pooled analysis of three RCTs demonstrates that up to 64 weeks of tildrakizumab is well tolerated in a large group of patients with moderate-to-severe psoriasis. Frequencies and exposure-adjusted rates of TEAEs, treatment-related AEs, serious AEs and discontinuations due to AEs with tildrakizumab treatment were lower than or comparable with placebo rates.
Frequencies and exposure-adjusted rates of MACEs with tildrakizumab treatment were low and comparable with placebo, indicating no increased risk of MACEs. Analysis of MACEs in the pooled analysis was selected as a prespecified AE of interest because patients with psoriasis are at increased risk for cardiovascular events, [18] [19] [20] and initial reports during the development of briakinumab, an IL-12/23 inhibitor, suggested an imbalance of MACEs between briakinumab and placebo. 24 The concerns regarding increased MACEs contributed to the withdrawal of the briakinumab application from the U.S. Food and Drug Administration. 25 However, a combined analysis of trials of the IL-12/23 inhibitor ustekinumab did not reveal an increased risk of MACEs compared with the general population or in patients with psoriasis. 26 Pooled analysis of 10 trials of secukinumab, an IL-17A inhibitor, also did not find an increased risk of MACEs. 17 Furthermore, a systematic review and meta-analysis of 38 RCTs found no indication of increased MACE risk vs. placebo with the licensed dose of any biologic for the treatment of moderate-to-severe psoriasis, including biologics that inhibit IL-23 or IL-17 (e.g. ustekinumab, secukinumab and ixekizumab). 27 To date, no pooled analyses investigating the risk of MACEs with the IL-23 inhibitor guselkumab have been published. Patients with psoriasis appear to have an increased risk of malignancies, including nonmelanoma skin cancer. 21 In the current pooled analysis, frequencies and exposure-adjusted rates of malignancies, nonmelanoma skin cancer and melanoma skin cancer with tildrakizumab treatment were similar to those with placebo, indicating no increased risk of these events with tildrakizumab. There were two cases of pancreatic cancer in patients treated with tildrakizumab 200 mg. The risk of infection is always a concern when a treatment inhibits a molecule in the immune system pathway. The infection frequency with tildrakizumab treatment during the placebo-controlled period was comparable with placebo, and exposure-adjusted rates during the full trial period were lower with tildrakizumab treatment than with placebo.
Worsening of inflammatory bowel disease 15 and increased frequency of Candida infections 16, 17 have been noted during treatment with IL-17 inhibitors. In the current analysis, no new or worsening events of inflammatory bowel disease or suicide were associated with tildrakizumab treatment. The frequency and exposure-adjusted rates of Candida infections with tildrakizumab were low and comparable with placebo. During the short duration of the placebo-controlled period, the frequencies of TEAEs, serious AEs and discontinuations due to AEs were comparable among the tildrakizumab doses and ETN. The frequency of treatment-related AEs was higher with ETN than with tildrakizumab or placebo, driven mainly by injection-site-related AEs. During the full trial period, the exposure-adjusted rates of TEAEs, treatment-related AEs, serious AEs and discontinuations due to AEs were all numerically higher with ETN than with the tildrakizumab doses. However, aside from injection-site reactions, the rates of prespecified AEs (e.g. MACEs, severe infections and malignancies) were comparable among the tildrakizumab doses and ETN. Injection-site reactions were notably higher with ETN.
The current analysis is limited by the short placebo exposure compared with tildrakizumab treatment, per the trial protocols. Furthermore, the number of patients receiving placebo and ETN was approximately half that of patients receiving each tildrakizumab dose. Longer-term follow-up studies are needed to determine fully the safety of tildrakizumab in regard to MACEs and malignancies. Nevertheless, up to 64 weeks of tildrakizumab treatment was well tolerated, with low rates of serious TEAEs, discontinuations due to AEs and AEs of clinical interest. There was no evidence of increased risk for AEs of interest associated with IL-17 inhibitors within the limits of cross-trial comparison. Analysis of data from long-term extension trials will provide further knowledge regarding the safety and tolerability of tildrakizumab. 
Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher's website: Fig S1. Trial designs. Appendix S1 Additional patient selection criteria. Table S1 Exposure-adjusted rates of specific adverse events during the placebo-controlled period (all patients as treated). Table S2 Detail of deaths occurring during the full trial period of the studies. Table S3 Adverse events of clinical interest in the placebocontrolled and full trial periods (all patients as treated).
